Pathocil
(Dicloxacillin)ApprovedSmall molecule
Pathocil is one of 51 small molecule programs targeting Endocarditis. It is currently in Approved.
3
Indications
5
Total Trials
1
Active Trials
50
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 3
Daliresp
AstraZenecaPhase 3
Pathocil
WWyeth-Lederle Vaccines
Approved
Tagamet
DDT MedTech, LLC
Phase 3
GR1802
GGenrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
Ketotifen Fumarate
Tanabe Pharma CorporationPhase 3
Prograf
VVeloxis Pharmaceuticals
Preclinical
Adtralza
LEO PharmaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Infections1 trial
Drug Interactions1 trial
Atopic Dermatitis1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
PATHOCIL
NDA NDA050011
Jan 1, 1982
DYNAPEN
NDA NDA050337
Jan 1, 1982
PATHOCIL
NDA NDA050092
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dicloxacillin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- WWyeth-Lederle Vaccines